Brian A. Whiteman

Array ( [id] => 16728141 [patent_doc_number] => 20210095288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => METHODS OF MODULATING NKX6.3 [patent_app_type] => utility [patent_app_number] => 17/044028 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11197 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17044028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17975821 [patent_doc_number] => 11492671 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => MiRNAs for treatment and in vitro diagnosis of drug resistant tumors [patent_app_type] => utility [patent_app_number] => 17/046478 [patent_app_country] => US [patent_app_date] => 2019-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 37 [patent_no_of_words] => 12288 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16681936 [patent_doc_number] => 10941403 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-09 [patent_title] => Microrna inhibitors as anti-cancer therapeutics [patent_app_type] => utility [patent_app_number] => 16/373452 [patent_app_country] => US [patent_app_date] => 2019-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 30 [patent_no_of_words] => 8711 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16373452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18732161 [patent_doc_number] => 11800872 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-31 [patent_title] => Systems, methods and composition of using RNase III mutants to produce sRNA to control host pathogen infection [patent_app_type] => utility [patent_app_number] => 17/044237 [patent_app_country] => US [patent_app_date] => 2019-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 38 [patent_no_of_words] => 34339 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17044237 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839835 [patent_doc_number] => 20210147847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => APTAMERS FOR TARGETED ACTIVATON OF T CELL-MEDIATED IMMUNITY [patent_app_type] => utility [patent_app_number] => 17/043784 [patent_app_country] => US [patent_app_date] => 2019-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38800 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14567453 [patent_doc_number] => 20190211333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => Targeting Ligands For Therapeutic Compounds [patent_app_type] => utility [patent_app_number] => 16/363108 [patent_app_country] => US [patent_app_date] => 2019-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16363108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590840 [patent_doc_number] => 10900091 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => miR-133a as a marker for colorectal cancer [patent_app_type] => utility [patent_app_number] => 16/361830 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 12 [patent_no_of_words] => 10524 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16361830 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496899 [patent_doc_number] => 20200048638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/357018 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 117368 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16357018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17527076 [patent_doc_number] => 11299749 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-12 [patent_title] => Cell-specific expression of modRNA [patent_app_type] => utility [patent_app_number] => 16/354814 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 93 [patent_no_of_words] => 16470 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16354814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16583118 [patent_doc_number] => 20210017520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => MICRO-RNA AND OBESITY [patent_app_type] => utility [patent_app_number] => 16/979777 [patent_app_country] => US [patent_app_date] => 2019-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16540981 [patent_doc_number] => 20200407394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA [patent_app_type] => utility [patent_app_number] => 16/966132 [patent_app_country] => US [patent_app_date] => 2019-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16966132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14896947 [patent_doc_number] => 20190292239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => VEGF-BINDING PROTEIN FOR BLOCKADE OF ANGIOGENESIS [patent_app_type] => utility [patent_app_number] => 16/291829 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18315295 [patent_doc_number] => 11629366 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => Method for selective translation of desired proteins in the presence of a specified nucleic acid ligand [patent_app_type] => utility [patent_app_number] => 16/290725 [patent_app_country] => US [patent_app_date] => 2019-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 6522 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16290725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16696961 [patent_doc_number] => 10947544 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Aptamer therapeutics useful in the treatment of complement-related disorders [patent_app_type] => utility [patent_app_number] => 16/289374 [patent_app_country] => US [patent_app_date] => 2019-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 78 [patent_no_of_words] => 40128 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16289374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17037100 [patent_doc_number] => 20210254058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => SHORT/SMALL HAIRPIN RNA MOLECULES [patent_app_type] => utility [patent_app_number] => 16/971893 [patent_app_country] => US [patent_app_date] => 2019-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55370 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16971893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18172861 [patent_doc_number] => 11572562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => Compositions and methods for inhibiting GYS2 expression [patent_app_type] => utility [patent_app_number] => 16/977152 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 10 [patent_no_of_words] => 22288 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16977152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17089998 [patent_doc_number] => 11118178 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-14 [patent_title] => Reduced size self-delivering RNAI compounds [patent_app_type] => utility [patent_app_number] => 16/270524 [patent_app_country] => US [patent_app_date] => 2019-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 95 [patent_figures_cnt] => 95 [patent_no_of_words] => 51419 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16270524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948454 [patent_doc_number] => 20210207145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => METHODS FOR THERAPEUTIC USE OF EXOSOMES AND Y-RNAS [patent_app_type] => utility [patent_app_number] => 16/966840 [patent_app_country] => US [patent_app_date] => 2019-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20317 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16966840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16622806 [patent_doc_number] => 20210041459 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => METHODS OF TREATING SPINAL MUSCULAR ATROPHY [patent_app_type] => utility [patent_app_number] => 16/963914 [patent_app_country] => US [patent_app_date] => 2019-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16963914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17097208 [patent_doc_number] => 20210284999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => APPLICATION OF MICRORNA-210 INHIBITOR IN PREPARATION OF DRUGS FOR TREATING INFLAMMATORY SKIN DISEASES [patent_app_type] => utility [patent_app_number] => 16/978778 [patent_app_country] => US [patent_app_date] => 2019-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16978778 [rel_patent_id] =>[rel_patent_doc_number] =>)